Objectives: Fecal calprotectin (FC) is widely used to monitor the activity of inflammatory bowel disease (IBD) and to tailor medical treatment to disease activity. Laboratory testing of fecal samples may have a turnaround time of 1-2 weeks, whereas FC home testing allows results within hours and thus enables a rapid response to clinical deterioration. Design and methods: Fifty-five stool samples were analyzed by the IBDoc ® Calprotectin Home
Introduction
Ulcerative colitis (UC) and Crohn's disease (CD) are the two most prevalent forms of inflammatory bowel disease (IBD), with the highest prevalence and incidence in Europe and North America. UC and CD can in most cases be distinguished by differences in clinical presentation, endoscopic and histological appearance, risk factors and genetic predisposition [1] . Continuous monitoring of IBD is crucial to tailor treatment to active disease, maintain remission and reduce the risk of relapse. Recent research has shown that apart from steroid-free remission and symptom control alone, achieving endoscopic and maybe even histological mucosal healing has a major impact on disease control and progression. Achieving mucosal healing minimizes hospital admissions and surgery, lowers the risk for relapse and intensification of medical therapy and improves quality of life [2] . Endoscopic procedures are unpleasant for the patient, time-consuming and bear the risk of intestinal perforation. Thus noninvasive monitoring of disease activity is preferable, though no ideal biomarker has been identified. FC is more sensitive than serum C-reactive protein (CRP) in reflecting disease activity in IBD [3] , and can be used to identify patients at risk of relapse and predict both endoscopic and histological mucosal healing [4] .
T
Calprotectin is a heterodimer of the two calcium-binding proteins, S100A8 and S100A9, and is elevated in serum in several inflammatory conditions [5] . Calprotectin is primarily released by activated neutrophils at sites of inflammation, and when measured in feces serves as an indirect estimate of the neutrophil infiltrate in the gastrointestinal tract [6] . Laboratory testing of fecal samples may require transportation from outpatients to the laboratory, and may have a turnaround time of 1-2 weeks, which hampers fast medical treatment response to relapses and increase the risk of clinical deterioration before treatment commences. In the capital region of Denmark fecal samples from outpatients are transported by the normal postal service, and at Copenhagen University Hospital Hvidovre 16% of the fecal samples received are either discarded because of prolonged transport (> 5 days) or results are released from the laboratory with caution, which decreases the clinical utility of the lab results and is costly. Home testing of FC achieves a faster turnaround time (hours) and enables patients and clinicians to act on FC results without delay. The aim of this study was to investigate the correlation between FC measured by the BÜHLMANN fCAL ® turbo assay on a Roche Cobas 6000 c501, and the BÜHLMANN home test kit, IBDoc ® using the CalApp ® for data transfer.
Material and methods

Sample collection, preparation and storage
All stool samples were collected in plastic tubes by the patients and sent in by ordinary mail. The samples were immediately frozen at −20°C upon receipt and analyzed within 1-2 days. A total of fifty-five stool samples were analyzed for direct comparison of ). respectively, as it is well established that the normal range for FC is considered to be < 50 µg/g [7] and clinical studies have proposed that FC concentrations in the range 150-250 µg/g can be used to distinguish between active disease and mucosal healing [7, 8] . Clinical data of the patients whose samples were studied were not collected. (at level 252.14 µg/g). The assay is subject to external quality control through participation in the EQUALIS external quality control scheme (EQUALIS, Uppsala, Sweden), with a deviation from the method mean (own output group) of 5.5% (mean value own group 316 µg/g) and −1.5% (mean value own group 1138 µg/g) respectively in the latest (June 2017) EQA distribution. FC was measured in parallel using the IBDoc ® Calprotectin Home Testing kit from BÜHLMANN Laboratories AG according to the instructions of the manufacturer. IBDoc ® is a lateral flow-based calprotectin test and the kit consists of a stool extraction device, the CALEX ® Valve, and a test cassette. An iPhone 5c was used to install the CalApp ® , enabling the phone to read the test cassette and calculate a quantitative calprotectin concentration. IBDoc ® is not subject to external quality control.
Biochemical measurements
Statistics
The correlation between FC (BÜHLMANN fCAL ® turbo) and FC (IBDoc ® ) was assessed by using Spearman's Rho correlation coefficient. The intermediate imprecision of both assays was calculated. Statistical analyses and graphics were performed using IBM SPSS Statistics version 22 (IBM, Armonk, NY, USA).
Results
Fifty-five samples were included in this study, covering clinically relevant concentrations in the range 38 -796 µg/g (BÜHLMANN fCal ® turbo). Fig. 1 shows the correlation between FC (BÜHLMANN fCAL ® turbo) and FC (IBDoc ® ), with a Spearman rank correlation coefficient of 0.887. Over FC concentrations close to clinically relevant cut off values (range 30-300 µg/g), the Spearman rank correlation coefficient was 0.689 (n = 36, minimum = 38 µg/g, maximum: 298 µg/g). The Bland-Altman plot (Fig. 2) found a median intra-individual variation of 40.8% in fecal samples collected on two consecutive days -most pronounced in patients with high levels of FC [11] . Thus considering the finding of a significant intraindividual day-to-day (and even within-day) variability of FC in IBD patients, the CV% in IBDoc ® seems less concerning [11, 12] .
Discriminating between active disease and mucosal healing is probably the most clinical relevant issue regarding the use of FC. Different levels of cut-off values to distinguish between active disease and mucosal healing have been proposed, most often in the range of 150-250 µg/g [7, 8] . A high intermediate imprecision at the cut-off range is of greatest concern as it increases the risk of false negatives. In this study we found the highest imprecision of 26.6% at samples with FC > 200 µg/g (mean 668.4 µg/g) which we do not view as clinically relevant. The EQUALIS external quality control scheme for FC on BÜHLMANN fCal ® turbo showed a deviation from our output group of 5.5% (mean value 316 µg/g) and −1.5% (mean value 1138 µg/g) respectively. From all output groups the deviation was 37.1% and 21.6% respectively. In general there is poor standardization between FC assays, making it difficult to define a uniform threshold to discriminate between active disease and remission [13] . In this study the tests was performed by skilled laboratory technicians, but in a clinical setting, the test is performed by patients themselves. The results obtained with the CalApp ® are automatically transferred to the IBDoc portal and the patient's doctor is notified, thus allowing rapid response to test results. Heida et al. investigated the self-reported usability of the IBDoc®, with 87% of the patient reporting that the test was not difficult to perform and 97% of the patients interested in using the home test in the future. A limitation to this finding though, was that the study participants were a priori interested in home testing [10] . Bello et al. found that female sex and less severe disease was associated with higher usability of the IBDoc®, and that younger people especially thought they would use the tool in the future [9] . Elkjaer et al. found that a web-guided "constant care" approach for UC patients -a web based program where patients are educated in UC, in recognizing relapse and in starting correct treatment guided by the e-health program and a web-doctor -increases patient's compliance, quality of life, empowerment to self-initiated treatment and reduces healthcare costs [14] .
Conclusions
This study suggests that IBDoc® is a suitable alternative for the assessment of disease activity in IBD patients. Point of care testing would reduce the turnaround time significantly and potentially improve the quality of treatment by enabling rapid responses to relapses. In addition, home testing may be the only viable alternative in situations where visits to outpatient clinics are difficult or mailing is precluded because of the poor stability of FC.
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